Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer

As a potential tumor suppressor, the detailed clinical application value of sorting nexin 1 (SNX1) has not been elucidated in colorectal cancer (CRC). The aim of the present study was to evaluate the expression of SNX1 in CRC tissues and to determine its correlation with clinicopathologic characteri...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology Vol. 37; no. 5; pp. 6619 - 6625
Main Authors: Bian, Zehua, Feng, Yuyang, Xue, Yao, Hu, Yaling, Wang, Qifeng, Zhou, Leyuan, Liu, Zhihui, Zhang, Jiwei, Yin, Yuan, Gu, Bing, Huang, Zhaohui
Format: Journal Article
Language:English
Published: Dordrecht Springer Netherlands 01.05.2016
Springer Nature B.V
Subjects:
Adult
Aged
Antineoplastic Agents - pharmacology
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell Line, Tumor
Cell Proliferation
Colorectal cancer
Colorectal Neoplasms - genetics
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Down-Regulation
Drug resistance
Drug Resistance, Neoplasm - genetics
Female
Fluorouracil - pharmacology
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Male
Medical prognosis
Middle Aged
Neoplasm Grading
Neoplasm Staging
Original Article
Prognosis
Sorting Nexins - genetics
Studies
Tumor Burden
Tumors
Sorting nexin 1 (SNX1)
Prognosis
Drug resistance
Colorectal cancer (CRC)
ISSN:1010-4283, 1423-0380
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As a potential tumor suppressor, the detailed clinical application value of sorting nexin 1 (SNX1) has not been elucidated in colorectal cancer (CRC). The aim of the present study was to evaluate the expression of SNX1 in CRC tissues and to determine its correlation with clinicopathologic characteristics and its impact on patient’s prognosis. We detected the expression of SNX1 mRNA in 72 CRC patients and SNX1 protein in 237 CRC patients by real-time polymerase chain reaction (RT-PCR) and immunohistochemical staining, respectively. Relationship between the expression of SNX1 and various clinicopathological features in these patients was evaluated. Both the mRNA and protein expression of SNX1 were remarkably decreased in CRC tissues compared with paired non-cancerous tissues, and the down-regulation of SNX1 protein was strongly associated with poor differentiation and poor overall survival (OS) rate of CRC patients. Ectopic SNX1 expression repressed CRC cell growth and promoted tumor sensitivity to most commonly used chemotherapeutic drugs (oxaliplatin and 5-Fluorouracil). In conclusion, overexpression of SNX1 may serve as a new therapeutic strategy for CRC.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-015-3814-3